NDA 203255 · Recordati Rare
Signifor Lar Kit
Pasireotide Pamoate · Intramuscular
OrphanLast checked: Nov 20, 2026Latest source record: Jul 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Dec 15, 2014
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 1 recruiting
FAERS reports
1,502
1,066 serious, 103 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 16, 2024.
SIGNIFOR LAR is a somatostatin analog indicated for the treatment of: Patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. ( 1.1 ) Patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. ( 1.2 ) 1.1 Acromegaly SIGNIFOR LAR is indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. 1.2 Cushing's Disease SIGNIFOR LAR is indicated for the treatment of patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.
Mechanism: SIGNIFOR LAR is an injectable cyclohexapeptide, somatostatin analog. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTR). There are 5 known human somatostatin receptor subtypes: SSTR 1, 2, 3, 4, and 5. These receptor subtypes are expressed in different tissues under normal physiological conditions. Somatostatin analogs bind to SSTRs with different potencies. Pasireotide binds with high affinity to 4 of the 5 SSTRs (see Table 4). Table 4 – Binding Affinities of Somatostatin (SRIF-14) and Pasireotide to the Five Human SSTR Subtypes (SSTR 1-5) Results are...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 29, 2018 Supplement 4 · Efficacy OrphanLabelLetter
- Dec 15, 2014 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
5 products under this application
- SIGNIFOR LAR KIT · PASIREOTIDE PAMOATE EQ 10MG BASE/VIAL · FOR SUSPENSION, INTRAMUSCULAR · Prescription
- SIGNIFOR LAR KIT · PASIREOTIDE PAMOATE EQ 40MG BASE/VIAL · FOR SUSPENSION, INTRAMUSCULAR · Prescription
- SIGNIFOR LAR KIT · PASIREOTIDE PAMOATE EQ 30MG BASE/VIAL · FOR SUSPENSION, INTRAMUSCULAR · Prescription
- SIGNIFOR LAR KIT · PASIREOTIDE PAMOATE EQ 60MG BASE/VIAL · FOR SUSPENSION, INTRAMUSCULAR · Prescription
- SIGNIFOR LAR KIT · PASIREOTIDE PAMOATE EQ 20MG BASE/VIAL · FOR SUSPENSION, INTRAMUSCULAR · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pasireotide Pamoate" as an intervention, any sponsor and status, largest first.
- Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell TumorRecruiting
University Hospital HeidelbergAcademic, hospital or other
NCT06456359 · 28 participants (planned) · Start Dec 19, 2024 · Primary completion Oct 2027
Drug: Signifor · For: Desmoplastic Small Round Cell Tumor; Synovial Sarcoma
Sites: Heidelberg, Germany; Stuttgart, Germany; Essen, Germany · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased169
- diabetes mellitus165
- hyperglycaemia163
- drug ineffective125
- diarrhoea121
- off label use120
- headache117
- fatigue105
- nausea97
- dizziness72
- blood pressure increased69
- asthenia60
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 6 |
| 2014 | 21 |
| 2015 | 60 |
| 2016 | 139 |
| 2017 | 138 |
| 2018 | 138 |
| 2019 | 128 |
| 2020 | 175 |
| 2021 | 96 |
| 2022 | 124 |
| 2023 | 157 |
| 2024 | 136 |
| 2025 | 118 |
| 2026 | 64 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Recordati Rare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.